XRP is testing long-term support near $1.06 after months of negative sentiment, with one analyst warning that a break below $1 could actually be a 'golden ticket' entry point. The token has shed about 24% over the past three months and remains more than 70% below its July 2025 all-time high near $3.65. At the time of writing, XRP was trading around $1.07, down 1% in 24 hours and nearly 3% over the past week.
The technical picture
Crypto analyst ChartNerd said on August 3 that XRP's prolonged weakness could set the stage for a major market repricing in the next few months. The analyst noted XRP is trading inside a falling wedge pattern and approaching a six-year support zone that previously preceded a large upward movement. ChartNerd warned that a move below $1 support would not be unexpected and described it as a 'golden ticket' entry point, stating 'The lower it goes, the better the long-term opportunity becomes.'
Fellow analyst EGRAG CRYPTO identified the $1.05 area as a 'battlefield' for XRP. A successful defense could push it back toward $1.10 and higher, while a breakdown could expose it to the $1 region. The decline has been attributed to a wider crypto correction rather than Ripple's fundamentals, according to ChartNerd.
ETF flows slow
Spot XRP ETFs recorded $27 million in net inflows in July, down from June's $60 million and well below May's $132 million. The drop highlights XRP's struggle to hold higher levels after its mid-July rally fizzled. The cooling ETF demand comes as the broader market digests recent volatility.
Ripple's moves
While XRP prices sag, Ripple has been active on the investment front. The company invested in Zilo and Licuido, two firms focusing on tokenized funds and institutional asset infrastructure. The deals signal Ripple's continued push into real-world asset tokenization, even as its native token faces headwinds.
ChartNerd described the current period as a normal correction within a larger trend, with nothing inherently wrong with the asset. The key question now is whether XRP can defend the $1.05 level — or if a dip below $1 will give patient buyers the entry they've been waiting for.
